> Yesterday, Cadence Pharmaceuticals filed an $86.3 million IPO with the SEC. The company currently has two Phase III products in development. Release
> Cangene today has filed an NDA for its recombinant human growth hormone product (rhGH) Accretropin with the FDA. Accretropin combats short stature in children with growth hormone deficiency and girls with Turner Syndrome. Release
> Chutes & Ladders: Merck's president of intercontinental human health, Per Wold-Olsen, has announced that he will retire. Wold-Olsen was the head of the company's prescription drug business in Europe, the Middle East, Africa, Latin American and Canada, as well as worldwide drug marketing. Report
> A federal court has upheld King Pharmaceuticals' patent for Altace, a treatment for high blood pressure. India's Lupin had been planning a generic version of the drug that would have infringed on one of King's patents. Report
> Cell Genesys has begun enrollment in a Phase I trial of CG0070 for the treatment of recurrent bladder cancer. Release
And Finally... Researchers from the University of Montana have potential treatments for cancer and migraines in the most unlikely place: a polluted lake. Article